London · Delayed Price · Currency is GBP · Price in USD Merck & Co. Company Description
Merck & Co., Inc. operates as a healthcare company worldwide.
The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands.
The company has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and anti-PD-1 therapy, as well as KEYTRUDA (pembrolizumab) in patients with advanced solid tumors.
Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
| Country | United States |
| Founded | 1891 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 75,000 |
| CEO | Robert Davis |
Contact Details
Address: 126 East Lincoln Avenue Rahway, New Jersey 07065 United States | |
| Phone | 908 740 4000 |
| Website | merck.com |
Stock Details
| Ticker Symbol | 0QAH |
| Exchange | London Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US58933Y1055 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert M. Davis J.D. | Chairman, President and Chief Executive Officer |
| Betty D. Larson | Executive Vice President and Chief Human Resources Officer |
| Richard R. DeLuca Jr. | Executive Vice President and President of Merck Animal Health |
| Dalton E. Smart III | Senior Vice President of Finance, Principal Accounting Officer and Global Controller |
| Peter Dannenbaum | Vice President of Investor Relations |
| Sanat Chattopadhyay | Executive Vice President and President of Merck Manufacturing Division |
| Dr. Eric H. Rubin M.D. | Senior Vice President of Global Clinical Oncology and Early-stage Oncology |
| Dr. Eliav Barr M.D. | Chief Medical Officer and Head of Global Clinical Development of Merck Research Laboratories |
| Dr. Joerg Koglin | Senior Vice President and Head of General Medicine - Global Clinical Development |
| Katherine Taylor | Senior Director and Head of Risk Evaluation and Adaptive Integrated Monitoring |